Oscar Health (OSCR) Stock May Be Undervalued Following Its AI Marketplace Launch

Oscar Health has delivered very strong long term gains for shareholders, yet the recent pullback raises a simple question for anyone looking at the stock today: is the current price still in line with what its earnings can support?

• Over the past 3 years, Oscar Health has produced a very large share price return, which puts extra focus on whether its earnings can justify that kind of move.
• Management is talking about higher future earnings per share and better medical loss ratios, which can shift how investors think about the profit base that underpins any P/E multiple applied to the stock.
• There is a second opinion on Oscar Health worth weighing. See what analysts think Oscar Health's shares could be worth.

The issue now is whether Oscar Health's current share price, after these gains and new earnings ambitions, is fully justified by the profits it is generating and expected to generate.

To put Oscar Health's earnings story in context, it can help to compare it with other insurers and healthcare platforms using 38 healthcare AI stocks.

Does Oscar Health Look Undervalued on Earnings?

A P/E lens works well for Oscar Health because management steers investor attention toward earnings per share targets and profitability milestones. On this measure, the stock trades on a P/E of 16.6x, which is below both the Insurance sector average of 10.7x and the peer group on 32.5x. The market implied fair P/E multiple for Oscar Health, which blends its growth profile, profitability record, size and risk, points to a higher ratio than where the shares change hands today.

Because the latest Investor Day set out an earnings roadmap, including EPS targets for 2027, the current P/E level appears not to be fully reflecting those ambitions. Despite that guidance around future EPS and operating leverage, Oscar Health still trades at a discount to the P/E level indicated by this tailored valuation framework, which suggests the market is applying a degree of caution to the story. Explore the numbers behind Oscar Health's P/E valuation.

The Oscar Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Oscar Health P/E puzzle leaves off by spelling out which views on future growth, profitability and earnings would need to hold for the stock to be worth meaningfully more or less than it is today on the market. Each scenario ties its valuation number to a specific view on where Oscar Health's growth, margins and risk profile might go next, giving you something concrete to revisit as fresh information comes through.

Oscar Health draws sharply different reactions, with some investors arguing it looks 95% undervalued while others frame it as 18% overvalued.

Bull case: 95% undervalued

"Suspicious of a value trap, I started digging into the operational engine to find the catch. Instead, the deeper I dug, the more the moat began to show…"

Discover why this Narrative puts Oscar Health at 95% undervalued.

Bear case: 18% overvalued

"Persistently high and rising medical loss ratios, now over 91 percent, coupled with a market-wide morbidity increase, threaten Oscar Health's path to sustainable profitability…"

Explore why this Narrative puts Oscar Health at 18% overvalued.

Oscar Health’s valuation still leaves one crucial issue on the table

Before you lean too hard on the earnings story, it is worth asking what the latest risk checks are quietly flagging in the background for Oscar Health. Take a closer look at 2 warning signs before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com